Mediators of social support and antiretroviral adherence among an indigent population in New York City

AIDS Patient Care and STDs

Volumn 16, Issue 9, 2002, Pages 431-439

  Simoni, Jane M ^a   Frick, Pamela A ^a   Lockhart, David ^a   Liebovitz, David ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEPRESSION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOWEST INCOME GROUP; MALE; NEGRO; PATIENT COMPLIANCE; PUERTO RICO; SELF CONCEPT; SELF REPORT; SOCIAL SUPPORT; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHI-SQUARE DISTRIBUTION; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HISPANIC AMERICANS; HIV INFECTIONS; HUMANS; MALE; MEDICAL INDIGENCY; MIDDLE AGED; NEW YORK CITY; PATIENT COMPLIANCE; SELF EFFICACY; SOCIAL SUPPORT;

EID: 0036740894     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729102760330272     Document Type: Article

References (50)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
2. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-454.
3. Valenti WM. Treatment adherence improves outcomes and manages costs. AIDS Read 2001;11:77-80.
4. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001;15:1181-1183.
5. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JSG. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000;23:360-361.
6. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
7. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999;282:1135-1149.
8. Salomon H, Wainberg MA, Brenner B, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS 2000;14:F17-23.
9. Yerly S, Kaiser L, Race E, Bru J-P, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999;354:729-733.
10. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? JAMA 1989;261:3273-3277.
11. Geest SD, Borgermans L, Gemoets H, et al. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation 1995;59:340-347.
12. Klerk ED, Linden SVD. Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic monitoring device. Br J Rheumatol 1996;35:60-65.
13. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load and development of drug resistance in an indigent population. AIDS 2000;14:357-366.
14. Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr 2002;29:S2-S10.
15. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999;13:1763-1769.
16. Martin-Fernandez J, Escobar-Rodriguez I, Campo-Angora M, Rubio-Garcia R. Evaluation of adherence to highly active antiretroviral therapy. Arch Intern Med 2001;161:2739-2740.
17. Nieuwkerk PT, Sprangers MA, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001;161:1962-1968.
18. Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol 1997;50:385-391.
19. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care 2000;12:255-266.
20. Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J AIDS Hum Retroviral 1998;18:117-125.
21. Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999;13(Suppl 1):S61-S72.
22. Kalichman SC, Ramachandran B, Catz S. Adherence to combination antiretroviral therapies in HIV patients of low health literacy. J Gen Intern Med 1999;14:267-273.
23. Wenger N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral (AR) adherence. Presented at: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999, 1999; Chicago.
24. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance. AIDS Care 1996;8:261-269.
25. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000;23:386-395.
26. Bozette SA. Derivation and properties of a brief health-related quality-of-life assessment instrument for use in HIV disease. J Acquir Immune Defic Syndr 1995;8:253-265.
27. Rosenstock IM. Patients' compliance with health regimens. JAMA 1975;234:402.
28. Erickson S, Ascione F, Kirking D, Johnson C. Use of a paging system to improve medication self-management in patients with asthma. J Am Pharm Assoc 1998;38:767-769.
29. Smith SR, Kirking DM, ACSUS (AIDS Costs and Services Utilization Survey). The effect of insurance coverage changes on drug utilization in HIV disease. J Acquir Immune Defic Syndr 2001;28:140-149.
30. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001;28:445-449.
31. Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis 2000;30(Suppl 2):S96-S116.
32. Bartlett JA, Demasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001;15:1369-1377.
33. Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the HERS study. J Acquir Immune Defic Syndr 2001;28:124-131.
34. DiMatteo MR, Mays R. Social support and serious illness. In: Gottlieb B (ed). Social Networks and Social Support. Beverly Hills, CA: Sage; 1981;117-148.
35. Turk DC, Salovey P, Litt MD. Adherence: A cognitive-behavioral perspective. In: Gerber KE, Nehemkis AM, (eds). Compliance: The Dilemma of the Chronically Ill. New York: Springer; 1981:44-72.
36. Becker MH, Maiman LA. Strategies for enhancing patient compliance. J Community Health 1980;6:113-135.
37. Earp JAL. The effects of social support and health professional home visits on patient adherence to hypertension regiments. Prev Med 1979;8:155.
38. Kirscht JP, Kirscht JL, Rosenstock IM. A test of interventions to increase adherence to hypertensive medical regimens. Health Educ Behav 1981;8:261-272.
39. Bandura A. Self-efficacy: Toward a unifying theory of behavioral change. Psychol Rev 1997;84:191-215.
40. Ickovics J. Measures of Adherence. Presented at: Adherence to New HIV Therapies: A Research Conference, 1997; Washington, D.C.
41. Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS 1997;11:1665-1670.
42. Treisman GJ, Angelina AF, Hutton HE. Psychiatric issues in the management of patients with HIV infection. JAMA 2001;286:2857-2864.
43. Wagner GJ, Remien RH, Carballo-Dieguez A, Dolezal C. Correlates of adherence to combination antiretroviral therapy among members of HIV-positive mixed status couples. AIDS Care 2002;14:105-109.
44. Roberts KJ. Barriers to and facilitators of HIV-positive patients' adherence to antiretroviral treatment regimens. AIDS Patient Care STDs 2000;14:155-168.
45. Schwarzer R, Dunkel-Schetter C, Kemeny M. The multidimensional nature of received social support in gay men at risk of HIV infection and AIDS. Am J Community Psychol 1994;22:319-339.
46. Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Measure 1992;1:385-401.
47. Weissman MM, Sholomakas D, Pottenger M, Prusoff BA, Locke BZ. Assessing depressive symptoms in five psychiatric populations: A validation study. Am J Epidemiol 1992;106:203-214.
48. Ilfeld FW. Further validation of a psychiatric symptom index in a normal population. Psychol Rep 1976;39:1215-1228.
49. Crowne D, Marlow D. Social Desirability Scale. In: The Approval Motive. New York: John Wiley and Sons Inc.; 1964:727-732.
50. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. J Person Soc Psychol 1981;51:1173-1182.